Program

Program Tuesday, May 19, 2015

7:15 AM - 8:15 AM
EDUCATIONAL SYMPOSIA
7:15 AM - 8:15 AM
Room: Grand Ballroom, Salon H (Level 5)
DEVELOPMENTS IN MEDICAL BIG DATA RESEARCH: UNITED STATES AND CHINA

(Sponsored by Analysis Group)

7:30 AM - 8:30 AM
ISPOR MEDICAL DEVICES & DIAGNOSTICS SPECIAL INTEREST GROUP OPEN MEETING (DIAGNOSTICS)
Room: Grand Ballroom, Salon K-L (Level 5)
All ISPOR members interested in the area of diagnostics are welcome to attend the ISPOR Medical Devices and Diagnostic Special Interest Group meeting. The current leadership members will be discussing the development of a new diagnostic project, new members welcome.
8:30 AM - 10:30 AM
WELCOME & SECOND PLENARY SESSION
8:30 AM - 8:35 AM
Room: Grand Ballroom, Salon A-F (Level 5)
WELCOME
Adrian Towse, MA, MPhil bio
2014-2015 ISPOR President and Director, Office of Health Economics, London, UK
8:35 AM - 8:45 AM
Room: Grand Ballroom, Salon A-F (Level 5)
INCOMING PRESIDENTIAL ADDRESS
Daniel Malone, PhD, RPh bio
2014-2015 ISPOR President-Elect, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA
8:45 AM - 9:00 AM
Room: Grand Ballroom, Salon A-F (Level 5)
2015 ISPOR AVEDIS DONABEDIAN OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARD
8:45 AM - 9:00 AM
Room: Grand Ballroom, Salon A-F (Level 5)
2015 ISPOR MARILYN DIX SMITH LEADERSHIP AWARD
8:45 AM - 9:00 AM
Room: Grand Ballroom, Salon A-F (Level 5)
2015 ISPOR VALUE IN HEALTH PAPER OF THE YEAR AWARD
8:45 AM - 9:00 AM
Room: Grand Ballroom, Salon A-F (Level 5)
2015 ISPOR AWARD FOR EXCELLENCE IN METHODOLOGY IN PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH
8:45 AM - 9:00 AM
Room: Grand Ballroom, Salon A-F (Level 5)
2015 ISPOR AWARD FOR EXCELLENCE IN APPLICATION OF PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH
8:45 AM - 9:00 AM
Room: Grand Ballroom, Salon A-F (Level 5)
2015 ISPOR BERNIE J. O’BRIEN NEW INVESTIGATOR AWARD
9:00 AM - 10:30 AM
Room: Grand Ballroom, Salon A-F (Level 5)
SECOND PLENARY SESSION: COST-EFFECTIVENESS AND CLINICAL PRACTICE GUIDELINES: HAVE WE REACHED A TIPPING POINT?
In recent years, both oncology and cardiology professional organizations have embraced the explicit consideration of cost-effectiveness and the value of treatments in developing and updating clinical practice guidelines and clinical pathways. This is a new development in the U.S. health care system, and one which is complicated by the pluralistic nature of the system. The impact that it could ultimately have on medical practice is not clear neither in terms of access to care and providers nor in terms of incentives for innovation. This session will explore the implications of this change for the range of stakeholders involved, including U.S. private insurers, clinicians, patients, and federal government programs.
Moderator: Lou Garrison, PhD bio
Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
Considering Cost-Effectiveness In Cardiology Clinical Guidelines: Progress and Prospects
Speaker: Mark A. Hlatky, MD bio
Professor of Health Research and Policy and Professor of Medicine (Cardiovascular Medicine), Stanford University School of Medicine, Stanford, CA, USA
Challenges in Measuring Cost and Value in Oncology: Making It Personal
Speaker: Peter P. Yu, MD, FACP, FASCO bio
Director of Cancer Research, Palo Alto Medical Foundation, Sunnyvale, CA and President, American Society of Clinical Oncology (ASCO), Alexandria, VA, USA
Clinical Guidelines: A NICE Way to Introduce Cost-Effectiveness Considerations?
Speaker: Michael Drummond, MCom, DPhil bio
Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
8:30 AM - 2:15 PM
RESEARCH POSTER PRESENTATIONS - SESSION III
10:30 AM - 11:00 AM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III
11:00 AM - 12:00 PM
ISSUE PANELS - SESSION II
Health Policy Development Using Outcomes Research Issues
11:00 AM - 12:00 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)

IP6: HOW SHOULD THE FDA REGULATE THE COMMUNICATION OF HEALTH ECONOMIC DATA BY PHARMACEUTICAL COMPANIES TO PAYERS?

Moderator:

Peter J. Neumann, ScD, Professor & Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA bio

Panelists:

Laurie Burke, MPH, RPh, Founder, LORA Group, Royal Oak, MD, USA

Joseph Jackson, PhD, Principal, Health Outcomes Insights LLC, Lavallette, NJ, USA

Albert F. Cacozza, JD, Partner, Ropes & Gray, Washington, DC, USA


11:00 AM - 12:00 PM
Room: Grand Ballroom, Salon H (Level 5)

IP7: NEW MODELS OF CANCER REIMBURSEMENT: ARE THERE CONSEQUENCES FOR SPENDING AND PATIENT HEALTH?

Moderator:

Amitabh Chandra, PhD, Director of Health Policy Research, John F. Kennedy School of Government, Harvard University, Cambridge, MA, USA

Panelists:

Andrew Briggs, DPhil, MSc, William R. Lindsay Professor of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK

Darius N. Lakdawalla, PhD, Quintiles Chair in Pharmaceutical Development and Regulatory Innovation, School of Pharmacy, University of Southern California, Los Angeles, CA, USA

Jennifer Malin, MD, PhD, Medical Director for Oncology, Anthem, Woodland Hills, CA, USA

Use of Real World Data Issues
11:00 AM - 12:00 PM
Room: Grand Ballroom, Salon G (Level 5)

IP8: ARE WE COMFORTABLE APPLYING EXISTING QUALITY-DRIVEN ADHERENCE MEASUREMENT METHODOLOGIES TO SPECIALTY PHARMACEUTICAL PRODUCTS AND WHAT ARE THE RISKS, ESPECIALLY IF USING ADMINISTRATIVE CLAIMS DATABASES?

Moderator:

Craig Schilling, PharmD, Chair, Pharmacy Quality Alliance (PQA) Adherence Committee and Vice President, Patient Programs, Optum, Eden Prairie, MN, USA

Panelists:

Richard Faris, PhD, MSc, RPh, Co-Chair, Pharmacy Quality Alliance (PQA) Specialty Pharmacy Products Task Force and Director, HECOR, UCB, Inc., Smyrna, GA, USA

Michael Ingham, MSc, Director, HECOR, Janssen Scientific Affairs, LLC, Horsham, PA, USA

Stephen M Lund, RPh, Executive Vice President, Strategic Initiatives, Senderra Rx Specialty Pharmacy, Richardson, TX, USA

Clinical Outcomes Research Issues
11:00 AM - 12:00 PM
Room: Grand Ballroom, Salon K-L (Level 5)

IP9: CONTINUOUS PATIENT ENGAGEMENT: HOW DO WE PARTNER WITH PATIENTS THROUGHOUT THE RESEARCH LIFE CYCLE?

Moderator:

C. Daniel Mullins, PhD, Professor & Chair, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA

Panelists:

Emil Chiauzzi, PhD, Research Director, PatientsLikeMe, Cambridge, MA, USA

Daniel Frye, JD, Executive Director, NJ Commission for the Blind and Visually Impaired, Newark, NJ, USA

Marvin Mack, Chief Executive Officer, Center for Mind & Esteem Development, Baltimore, MD, USA

Economic Outcomes Research Issues
11:00 AM - 12:00 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)

IP10: EARLY ACCESS TO MEDICINES: WHAT IS IN IT FOR PAYERS?

Moderator:

Adam Heathfield, PhD, Senior Director, Global Health and Value Innovation Center, Pfizer, Surrey, UK

Panelists:

Adrian Towse, MA, MPhil, Director, Office of Health Economics (OHE), London, UK bio

Mark Trusheim, MS, Visiting Scientist & Executive in Residence, Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA, USA

Dan Ollendorf, PhD, Chief Review Officer, Institute for Clinical and Economic Review, Boston, MA, USA

12:00 PM - 2:15 PM
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III
12:15 PM - 1:15 PM
EDUCATIONAL SYMPOSIA
12:15 PM - 1:15 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)
DISSEMINATION OF HEALTH ECONOMIC EVIDENCE TO US PAYERS UNDER FDAMA SECTION 114 – LESSONS FROM THE PAST AND NEW GUIDANCE EXPECTED

(Sponsored by Xcenda)

12:30 PM - 2:00 PM
ISPOR MEDICAL DEVICES & DIAGNOSTICS SPECIAL INTEREST GROUP OPEN MEETING (MEDICAL DEVICES)
Room: Grand Ballroom, Salon G (Level 5)
Martin Ho from the Center for Devices and Radiological Health (CDRH), FDA will present “Incorporating Patient Preferences into Regulatory Process.” All ISPOR members interested or working in the area of medical devices are welcome to attend this Special Interest Group meeting. After the FDA presentation and discussion members will have the opportunity to discuss a new working group proposal on medical devices.
Discussion Leader: Anindiata Saha
Director, External Expertise and Partnerships, Center for Devices and Radiological Health, U.S. Food and Drug Administration
Discussion Leader: Martin Ho
Center for Devices and Radiological Health, U.S. Food and Drug Administration
1:15 PM - 2:00 PM
ISPOR GENERAL BUSINESS MEETING
Room: Grand Ballroom, Salon I (Level 5)
Attendees are invited to ISPOR’s Annual Meeting, the official business meeting of the Society, to hear reports and updates to the membership. Learn about what ISPOR has accomplished over the past year, meet leaders and the new CEO & Executive Director. The results of the recent ISPOR member survey will also be presented.
1:15 PM - 2:15 PM
POSTER AUTHOR DISCUSSION HOUR - SESSION III
2:15 PM - 3:15 PM
ISSUE PANELS - SESSION III
Health Policy Development Using Outcomes Research Issues
2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)

IP11: THE $2.6 BILLION QUESTION: WHY ARE DRUG DEVELOPMENT COSTS RISING AND CAN WE AFFORD IT? (Invited Issue Panel)

Moderator:

Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA bio

Panelists:

Joseph A. DiMasi, PhD, Director of Economic Analysis, Tufts Center for the Study of Drug Development, Tufts University, Boston, MA, USA bio

Patricia M. Danzon, PhD, Celia Moh Professor, The Wharton School, University of Pennsylvania, Philadelphia, PA, USA bio

Adrian Towse, MA, MPhil, Director, Office of Health Economics (OHE), London, UK bio


2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon H (Level 5)

IP12: PATIENT-FOCUSED DRUG DEVELOPMENT: ARE POLICY MAKERS LISTENING?

Moderator:

John F P Bridges, PhD, Associate Professor, Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Panelists:

Mark Walderhaug, PhD, Associate Director for Risk Assessment, Center for Biologics Evaluation & Research, Office of Biostatistics & Epidemiology, U.S. Food & Drug Administration, Silver Spring, MD, USA

Holly Peay, PhD, Senior Vice President, Community Research, Parent Project Muscular Dystrophy, Hackensack, NJ, USA

Frank W Rockhold, PhD, Senior Vice President, Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Cary, NC, USA


2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)

IP13: CAN THE EUNETHTA HTA CORE MODEL© HELP TO ENSURE AN ALIGNED CONCEPT OF VALUE BETWEEN HTA, DECISION MAKERS/PAYERS, AND PHARMA INDUSTRY?

Moderator:

Finn Boerlum Kristensen, MD, PhD, Secretariat Director, Danish Health and Medicines Authority, Copenhagen, Denmark bio

Panelists:

Melvin Olson, PhD, Head of HEOR Excellence, Novartis Pharma, Basel, Switzerland

David Shum, PharmD, MBA, Head, Market Access, F. Hoffmann La Roche, Mississauga, ON, Canada

Chander Sehgal, MD, MBA, Director, Common Drug Review (CDR) & Optimal Use of Drugs, Canadian Agency for Drugs and Technologies in Health (CADTH), Toronto, ON, Canada

Use of Real World Data Issues
2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon G (Level 5)

IP14: DISTINGUISHING BIOSIMILARITY – HOW CAN WE GENERATE REAL-WORLD EVIDENCE TO SUPPORT DECISION-MAKING?

Moderator:

Nancy A. Dreyer, PhD, MPH, Senior Vice President, Global Chief of Scientific Affairs, Real-World & Late Phase Research, Quintiles, Cambridge, MA, USA

Panelists:

Robert W Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA

Jaclyn L Bosco, PhD, MPH, Director of Epidemiology, Real-World & Late Phase Research, Quintiles, Cambridge, MA, USA

Jeff White, PharmD, MS, Director, Drug Evaluation and Clinical Analytics, Clinical Pharmacy Policy, Anthem, Inc., Costa Mesa, CA, USA

Economic Outcomes Research Issues
2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon K-L (Level 5)

IP15: THE CONTROVERSIAL ROLE OF COST-EFFECTIVENESS ANALYSES (CEA) AND INCREMENTAL COST-EFFECTIVENESS RATIO (ICER) THRESHOLDS IN VALUE-BASED ASSESSMENTS (VBA) OF HEALTH TECHNOLOGIES: WHAT ARE THE FUTURE CHALLENGES?

Moderator:

Zeba M. Khan, RPh, PhD, Vice President, Celgene Corporation, Summit, NJ, USA

Panelists:

Michael Schlander, MD, PhD, MBA, Chairman & Scientific Director, Institute for Innovation & Valuation in Health Care, University of Heidelberg, Wiesbaden, Germany

Ron Akehurst, PhD, Professor Emeritus of Health Economics, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

John Proach, MBA, Executive Vice President, Pricing and Market Access, Market Access Solutions LLC, Raritan, NJ, USA

3:15 PM - 3:45 PM
BREAK & EXHIBITS VIEWING
3:45 PM - 4:45 PM
WORKSHOPS - SESSION II
Health Policy Development Using Outcomes Research
3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon I (Level 5)
W8: DESIGN OF BUNDLED PAYMENT IN THE AMBULATORY SETTING OF CARE
Discussion Leaders:

Mike Ciarametaro, MBA, Director of Research, National Pharmaceutical Council, Washington, DC, USA

Joshua T. Cohen, PhD, Associate Professor, Center for the Evaluation of Value and Risk in Health,Tufts Medical Center, Boston, MA, USA

Lili Brillstein, MPH, Director, Episodes of Care, Horizon Healthcare Innovations, Newark, NJ, USA

Michael del Aguila, PhD, Vice President, HEOR US Medical, Bristol-Myers Squibb, New York, NY, USA

Use of Real World Data
3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon J (Level 5)
W9: METHODOLOGICAL CHOICES FOR ANALYZING CLUSTER-CORRELATED DATA IN LARGE PATIENT DATABASES
Discussion Leaders:

Steve Sherman, MPH, Director, HEOR, Creativ-Ceutical, Chicago, IL, USA

Katia Thokagevistk, PhD, Manager, HEOR, Creativ-Ceutical, Paris, France

Firas Dabbous, PhD, Research Analyst, Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL, USA

Samuel Aballéa, PhD, Vice President, HEOR, Creativ-Ceutical, Paris, France


3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon K-L (Level 5)
W10: RARE DISEASES IN THE ERA OF BIG DATA: SELECTION BIAS IN SMALL SAMPLES
Discussion Leaders:

Nicole M. Engel-Nitz, Ph.D., Senior Researcher, HEOR, Optum, Eden Prairie, MN, USA

Zhimei Liu, PhD, Director, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Cori Blauer-Peterson, MPH, Senior Research Analyst, Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA

Jonathan C. Johnson, MS, Associate Director, HEOR, Optum, Eden Prairie, MN, USA

Clinical Outcomes Research
3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)
W11: CAN WE MAKE COMPARATIVE EFFECTIVENESS USEFUL FOR CLINICIANS AND PATIENTS OR IS IT JUST FOR HEALTH TECHNOLOGY ASSESSMENTS?
Discussion Leaders:

Edward J Mills, PhD, MSc, Visiting Associate Professor, Stanford University, Stanford, CA, USA

Christopher O'Regan, MSc, Head of Health Technology Assessment & Outcomes, Merck Sharp & Dohme Limited, Hertfordshire, UK

Sonal Singh, MD, MPH, Professor, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA

Economic Outcomes Research
3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)
W12: ISSUES TO CONSIDER WHEN ESTIMATING HEALTH CARE COSTS WITH GENERALIZED LINEAR MODELS (GLMS): TO GAMMA/LOG OR NOT TO GAMMA/LOG? THAT IS THE NEW QUESTION
Discussion Leaders:

Jalpa A. Doshi, PhD, Associate Professor of Medicine & Director, Economic Evaluations Unit, Center for Evidence-based Practice and Director, Value-based Insurance Design Initiatives, Center for Health Incentives and Behavioral Economics, General Internal Medicine, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA

Henry Glick, PhD, Professor of Medicine, Division of Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA

Andrew Briggs, DPhil, MSc, William R. Lindsay Professor of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK

Patient-Reported Outcomes & Patient Preference Research
3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon G (Level 5)
W13: PATIENT- AND OBSERVER-REPORTED OUTCOMES (PROS & OBSROS) MEASUREMENT IN RARE DISEASE CLINICAL TRIALS — EMERGING GOOD PRACTICES
Discussion Leaders:

Katy Benjamin, PhD, MS, Director, Patient Reported Outcomes, ICON, Bethesda, MD, USA

Eleanor Perfetto, PhD, MS, Associate Professor, Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD, USA

Laurie Burke, MPH, RPh, Founder, LORA Group, Royal Oak, MD, USA

Donald L. Patrick, PhD, MSPH, Professor, Seattle Quality of Life Group and Biobehavioral Cancer Training Program, University of Washington, Seattle, WA, USA


3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon H (Level 5)
W14: CHARTING A PATH FOR THE ELICITATION OF PREFERENCES: PERSPECTIVES ON THE EFFECTIVE USE OF PREFERENCE-ELICITATION METHODS
Discussion Leaders:

Josephine A. Mauskopf, PhD, MHA, MA, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA

Maarten J. IJzerman, PhD, Professor & Chair, Department of Health Technology & Services Research, University of Twente and MIRA Institute for Biomedical Technology & Technical Medicine, Enschede, The Netherlands

Juan Marcos Gonzalez, PhD, Senior Research Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA

3:45 PM - 7:45 PM
RESEARCH POSTER PRESENTATIONS - SESSION IV
5:00 PM - 6:00 PM
WORKSHOPS - SESSION III
Health Policy Development Using Outcomes Research
5:00 PM - 6:00 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)
W15: THE ISPOR MCDA TASK FORCE: HOW BEST TO USE IT IN HEALTH CARE DECISION MAKING
Discussion Leaders:

Maarten J. IJzerman, PhD, Professor & Chair, Department of Health Technology & Services Research, University of Twente and MIRA Institute for Biomedical Technology & Technical Medicine, Enschede, The Netherlands

Nancy Devlin, PhD, Director of Rearch, Office of Health Economics, London, UK

Praveen Thokala, PhD, Research Fellow, School of Health and Related Research, University of Sheffield, Sheffield, UK

Kevin Marsh, PhD, Senior Director, Modelling and Simulation, Evidera, London, UK

Use of Real World Data
5:00 PM - 6:00 PM
Room: Grand Ballroom, Salon H (Level 5)
W16: MAXIMIZING THE UTILITY OF REAL WORLD EVIDENCE: INTEGRATION OF STRUCTURED EMR DATA, UNSTRUCTURED EMR DATA, AND BILLING DATA FOR ECONOMICS AND OUTCOMES RESEARCH IN ONCOLOGY
Discussion Leaders:

Mark S Walker, PhD, Vice President of Scientific Affairs, Vector Oncology, Memphis, TN, USA

Kathy L. Schulman, MS, Managing Director, Outcomes Research Solutions, Inc., Bolton, MA, USA

Arliene Ravelo, MPH, Associate Director, US Medical Affairs, Genentech, Inc., South San Francisco, TN, USA

Kim Saverno, PhD, RPh, Director of Pharmacoeconomics, Vector Oncology, Memphis, TN, USA


5:00 PM - 6:00 PM
Room: Grand Ballroom, Salon K-L (Level 5)
W17: INFORMATICS AND INTEROPERABILITY: SPEAKING THE SAME LANGUAGE
Discussion Leaders:

Scott D Nelson, PharmD, MS, Post­doctoral Fellow, Medical Informatics, Department of Veterans Affairs, Salt Lake City, UT, USA

Olivier Bodenreider, MD, PhD, Branch Chief, Cognitive Science Branch, U.S. National Library of Medicine, Bethesda, MD, USA

Richard Boyce, PhD, Assistant Professor, Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA

Daniel C. Malone, PhD, RPh, FAMCP, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College, University of Arizona, Tucson, AZ, USA bio

Clinical Outcomes Research
5:00 PM - 6:00 PM
Room: Grand Ballroom, Salon I (Level 5)
W18: SURVIVING THE SUBMISSION: BEST PRACTICES IN OVERALL SURVIVAL EXTRAPOLATION IN ONCOLOGY
Discussion Leaders:

Sanatan Shreay, PhD, Associate Director, Gilead Sciences, Foster City, CA, USA

Andrew Briggs, DPhil, MSc, William R. Lindsay Professor of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK

Rachel Beckerman, PhD, Principal, Value Demonstration, CBPartners, New York, NY, USA

Petros Pechlivanoglu, PhD, Health Economist, Toronto Health Economics and Technology Assessment Collaborative, Toronto, ON, Canada

Economic Outcomes Research
5:00 PM - 6:00 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)
W19: MODELING IN ONCOLOGY: THE TAMING OF THE SHREWS?
Discussion Leaders:

Noemi Muszbek, MSc, Senior Research Scientist, Evidera, London, UK

Sorrel Wolowacz, PhD, Head, European Health Economics, RTI Health Solutions, Manchester, UK

Agnes Benedict, MSc, Executive Director, Evidera, Budapest, Hungary


5:00 PM - 6:00 PM
Room: Grand Ballroom, Salon G (Level 5)
W20: INCORPORATING SOCIAL VALUES INTO COST-EFFECTIVENESS ANALYSIS
Discussion Leaders:

Christopher McCabe, MSc, PhD, Professor, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada

Mike Paulden, MA, MSc, Senior Research Associate, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada

James F. O'Mahony, PhD, Post-Doctoral Researcher, Department of Health Policy & Management, Trinity College Dublin, Dublin, Ireland

Patient-Reported Outcomes & Patient Preference Research
5:00 PM - 6:00 PM
Room: Grand Ballroom, Salon J (Level 5)
W21: STATISTICAL METHODS USED FOR THE ASSESSMENT OF NON-REDUNDANCY AMONG CLINICAL TRIAL ENDPOINTS
Discussion Leaders:

Elizabeth D. Bacci, PhD, Senior Research Associate, Outcomes Research, Evidera, Seattle, WA, USA

Randall H. Bender, PhD, Senior Psychometric Statistician, Outcomes Research, Evidera, Bethesda, MD, USA

Joseph C Cappelleri, PhD, MPH, MS, Senior Director, Pfizer Inc., Groton, CT, USA

Kathleen W. Wyrwich, PhD, Executive Director, Center of Excellence, Outcomes Research, Evidera, Bethesda, MD, USA

6:00 PM - 7:45 PM
EXHIBITORS' WINE & CHEESE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION IV
6:15 PM - 7:15 PM
ISPOR FORUMS - SESSION II

6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)
F8: INCORPORATING EQUITY INTO HTA: METHODS, TOOLS AND APPLICATIONS IN LATIN AMERICA
Moderator:

Manuel Espinoza, MD, MSc, PhD, Assistant Professor, Department of Public Health & Coordinator, Unit of Health Technology Assessment, Center for Clinical Investigation, Catholic University of Chile, Santiago, Chile

Speakers:

Praveen Thokala, MASc, PhD, Research Fellow, University of Sheffield, Sheffield, UK

Clarice Petramale, MD, Director, Department of Management and Health Technology Incorporation, Secretariat of Science, Technology and Strategic Input, Minister of Health, Brasilia, Brazil

Alexandre Lemgruber, Regional Advisor in Health Technologies, Pan American Health Organization (Invited), Washington, DC, USA

Mike Paulden, MA, MSc, Senior Research Associate, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon G (Level 5)
F9: MANAGING COSTS AND IMPROVING QUALITY OF HEALTH CARE IN ASEAN
Moderator:

Surachat Ngorsuraches, PhD, Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkla, Thailand

Speakers:

Thuy Nguyen, PhD, Lecturer, Ho Chi Minh City University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam

Soraya Azmi, MD, MPH, Managing Director, Azmi Burhani Consulting, Petaling Jaya, Malaysia

Bayu Teja Muliawan, Director, Pharmaceutical Service, Ministry of Health of the Republic of Indonesia, Jakarta, Indonesia

Miny Lu, MD, PhD, Director, Healthcare Economics, Policy and Reimbursement, Medtronic, Singapore, Singapore


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)
F10: THE ISSUES AND CHALLENGES FACING THE LIFE SCIENCE INDUSTRY TODAY
Moderator:

John O’Donnell, PhD, Vice President, Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb Co., Princeton, NJ, USA

Speakers:

Donald Yin, PhD, Associate Vice President, Merck & Co. Inc., Lebanon, NJ, USA

James F. Murray, PhD, Research Fellow, Global Health Outcomes - COE, Eli Lilly and Company, Carmel, IN, USA


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon K-L (Level 5)
F11: MANAGED ENTRY AGREEMENTS (MEA) IN EGYPT, LEBANON, SAUDI ARABIA, AND UNITED ARAB EMIRATES
Moderator:

Abdulaziz H. Al-Saggabi, MSc, PharmD, President, ISPOR Saudi Arabia Chapter and Director, Drug Policy & Economics Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia

Speakers:

Mahmoud Elmahdawy, PharmD, President, ISPOR Egypt Chapter, Chair-Elect , ISPOR Africa Network and Administrations Manager, Hospital Pharmacy, Ministry of Health, Cairo, Egypt

Ola Ghaleb Al Ahdab, PhD, President, ISPOR United Arab Emirates Chapter and, Pharmaceutical Advisor & Project Manager, Registration and Drug Control Department, Ministry of Health, Abu Dhabi, United Arab Emirates

Soumana Nasser, PharmD, Clinical Associate Professor, Chair, Pharmacy Practice Department, School of Pharmacy, Lebanese American University, Byblos, Lebanon


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon H (Level 5)
F12: FUNDING HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL AND EASTERN EUROPEAN COUNTRIES: LOW PUBLIC BUDGET REFLECTS LOW PUBLIC PRIORITY?
Moderator:

Vladimir Zah, PhD candidate and Health Economics Consultant & Founder, ZRx Outcomes Research Inc., Belgrade, Serbia and Montenegro

Speakers:

Joanna Lis, PhD, President, ISPOR Poland Chapter, Adjunct Professor, Pharmacoeconomics Department, Medical University of Warsaw, and Director, Market Access, Sanofi, Warsaw, Poland

Vitaly Omelianovsky, MD, PhD, DSc, President, ISPOR Russia HTA Chapter, Professor & Director, Center for Health Technology Assessment of the Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia

John Yfantopoulos, PhD, President, ISPOR Greece Chapter and Professor of Health Economics, School of Economics and Political Science, University of Athens, Athens, Greece

Zoltán Kaló, PhD, MD, MSc, Chair, ISPOR CEE Network Executive Committee, Professor of Health Economics, Department of Health Policy and Health Economics, Eötvös Loránd University (ELTE), Founder & CEO, Syreon Research Institute, Budapest, Hungary


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon I (Level 5)
F13: THE ROLE OF HTA IN THE QUEST TOWARDS UNIVERSAL COVERAGE IN MEXICO: A GOVERNMENT, ACADEMIC AND INDUSTRY PERSPECTIVE
Moderator:

César Alberto Cruz Santiago, MD, PhD, Advisor, Medical Director Area, PEMEX (Petróleos Mexicanos), Mexico City, Mexico

Speakers:

Gabriela Andrea Luna Ruíz, PhD, Professor, Economics Department, Universidad Iberoamericana, Ciudad de México, Mexico City, Mexico

Adolfo Hernández-Garduño, MD, MSc, PhD, Access Planning Senior Manager, Access Department, Janssen Cilag Mexico, Mexico City, Mexico

Jocelyn Ramírez Gámez, MSc, Pharmacoeconomics Manager, Government Sales, Eli Lilly, Mexico City, Mexico

6:45 PM - 7:45 PM
POSTER AUTHOR DISCUSSION HOUR - SESSION IV
8:00 PM - 11:30 PM
ISPOR SOCIAL EVENT

ISPOR SOCIAL EVENT - Join colleagues for a “Rocking Evening” at the Hard Rock Café! Back By Popular Demand – Live Music by The ISPOR Monte Carlos!

Click Here For Additional Information

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.